Jasper Therapeutics, Inc. is under legal scrutiny following a class action lawsuit filed by DJS Law Group. The case alleges the company violated key provisions of the Securities Exchange Act, potentially impacting the rights and investments of shareholders.
Novo Nordisk A/S shareholders who purchased their securities between May 7, 2025, and July 28, 2025, are advised by Rosen Law Firm to consider legal action. With the lead plaintiff deadline set for September 30, 2025, investors are encouraged to act promptly to secure potential compensation.
Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against RxSight, Inc., claiming that top executives made false and misleading statements in violation of federal securities laws. Investors who suffered substantial losses are encouraged to join the lawsuit before the September 22, 2025 deadline.
The Schall Law Firm has announced a class action lawsuit against Vestis Corporation (NYSE: VSTS) for alleged violations of federal securities laws. Investors are being reminded of their opportunity to participate.
Investors who purchased American Depositary Shares of Reckitt Benckiser between January 13, 2021, and July 28, 2024, may have the opportunity to lead a securities fraud class action lawsuit. Rosen Law Firm has filed the suit, and the deadline to move the court to serve as lead plaintiff is August 4, 2025.
Levi & Korsinsky, LLP has filed a class action lawsuit against Quantum Computing Inc., alleging that the company engaged in securities fraud by overstating the capabilities of its quantum technologies. Investors affected between March 2020 and January 2025 are encouraged to join the lawsuit.
Investors in Venture Global, Inc. have until April 18 to seek the role of lead plaintiff in a federal securities class action filed against the company. Leading law firm Faruqi & Faruqi, LLP is investigating potential claims on behalf of those who suffered significant losses.
The Rosen Law Firm has announced that investors of The Trade Desk, Inc. have the opportunity to lead a securities fraud lawsuit against the company. The legal action pertains to allegations that may have affected shareholders.
Cassava Sciences is facing a class-action lawsuit following the failure of its Alzheimer’s drug candidate, simufilam, in Phase 3 trials. Investors allege securities fraud after the company’s stock plummeted by over 80% in a single day.
ASP Isotopes Inc. faces a class action lawsuit alleging that the company misled investors and violated federal securities laws, resulting in significant financial losses. Investors who purchased stock during the specified period are urged to take action before February 3, 2025.